The AstraZeneca new crown vaccine was 75 per cent effective against the mutated virus found in the UK

The new crown vaccine, developed jointly by Oxford University and AstraZeneca, was 75 per cent effective against the mutated strain found in the UK.
In a study published online Friday, researchers examined blood samples from 256 participants in a clinical trial and less than a third were infected with the new virus variant, the Wall Street Journal said.
The researchers eventually found that the vaccine elicited an effective immune response against the new strain of the virus in 75 percent of the symptomatic cases, and in about two-thirds of the cases when the asymptomatic cases were included.
The Wall Street Journal stresses that the findings are small and preliminary, and haven’t been formally reviewed by other scientists.
Data from the ChadoX1 vaccine trial in the United Kingdom showed that the AstraZeneca/Oxford New Crown vaccine could protect against not only the original virus but also the new variant B.1.1.7, said Andrew Pollard, lead investigator of the Oxford vaccine trial.
Co-developer Sarah Gilbert said that while the vaccine was effective against the strain found in the UK, it may need to be adapted to future strains and we are working with AstraZeneca to optimise it if necessary.
, Reuters reported the news from Oxford University, the university is introduced, the study was published in a preprint on without peer review, and detailed analysis of the recent research results, the results showed that after vaccination, viruses and viral load reduction of time, this can lead to the spread of the disease.
On November 23, 2020, AstraZeneca announced that its new crown vaccine AZD1222, in collaboration with the University of Oxford, is effective against Novel Coronavirus with an average efficacy of 70%.
The vaccine was authorised for emergency use in the UK on 30 December 2020.
On January 29, the European Union’s Medicines Agency approved the AstraZeneca vaccine for emergency use in 27 EU countries.
The problem of virus mutation has become an important issue in the global research and development of new crown vaccines.
, surging news previously reported, in view of the strains in the local time on February 4, Britain launched a test, will the Pfizer and astrazeneca UK production of two kinds of new crown in a two doses of the vaccine in the course of “mixed inoculation”, thus can cause “enhanced” immune response, and can fight mutated virus.
Other vaccines worldwide have published data or conducted further studies targeting novel coronavirus variants.
On January 28th Novavax, an American biotech company, said its new crown vaccine was more than 85% effective against a new crown mutation found in Britain;
Johnson & Johnson announced on January 29 that its new crown vaccine, Ad26.COV2.s, is also effective against the new crown mutant strain of the virus initially discovered in South Africa.
On January 25, Modena announced the initiation of preclinical and phase 1 clinical trials to test an mRNA vaccine against a novel coronavirus mutant strain (mRNA-1273.351) as an enhanced vaccine against the B.1.351 variant, which was first discovered in the Republic of South Africa.
In the case of the new crown vaccine from Germany’s Biontech, an early in vitro study showed that the vaccine provided the same protection against the mutated virus found in the UK, but the South African variant is still under study.

Leave a Reply

Your email address will not be published. Required fields are marked *